A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

PHASE3CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Asthma
Interventions
DRUG

Albuterol MDPI

90 mcg/actuation of the multidose dry powder inhaler (MDPI).

DRUG

Placebo

Matching Placebo delivered via a multidose dry powder inhaler (MDPI).

DRUG

ProAir HFA inhaler

Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.

Trial Locations (52)

Unknown

Teva Investigational Site 12496, Birmingham

Teva Investigational Site 12500, Mobile

Teva Investigational Site 12481, Little Rock

Teva Investigational Site 12515, Anaheim

Teva Investigational Site 12505, Costa Mesa

Teva Investigational Site 12476, Huntington Beach

Teva Investigational Site 12519, Los Angeles

Teva Investigational Site 12484, Mission Viejo

Teva Investigational Site 12510, Riverside

Teva Investigational Site 12483, Rolling Hills Estates

Teva Investigational Site 12511, Sacramento

Teva Investigational Site 12485, Stockton

Teva Investigational Site 12512, Centennial

Teva Investigational Site 12522, Gainesville

Teva Investigational Site 12535, Hollywood

Teva Investigational Site 12526, Miami

Teva Investigational Site 12516, Orlando

Teva Investigational Site 12517, Tamarac

Teva Investigational Site 12527, Vero Beach

Teva Investigational Site 12513, Winter Park

Teva Investigational Site 12486, Gainesville

Teva Investigational Site 12497, Lawrenceville

Teva Investigational Site 12480, Savannah

Teva Investigational Site 12508, Shiloh

Teva Investigational Site 12518, Iowa City

Teva Investigational Site 12523, Covington

Teva Investigational Site 12495, Warrensburg

Teva Investigational Site 12509, Northfield

Teva Investigational Site 12524, Brooklyn

Teva Investigational Site 12473, Raleigh

Teva Investigational Site 12477, Cincinnati

Teva Investigational Site 12525, Cleveland

Teva Investigational Site 12502, Middleburg Heights

Teva Investigational Site 12478, Oklahoma City

Teva Investigational Site 12487, Oklahoma City

Teva Investigational Site 12506, Oklahoma City

Teva Investigational Site 12492, Tulsa

Teva Investigational Site 12507, Gresham

Teva Investigational Site 12501, Normal Square

Teva Investigational Site 12493, Pittsburgh

Teva Investigational Site 12488, Upland

Teva Investigational Site 12514, Greenville

Teva Investigational Site 12474, Orangeburg

Teva Investigational Site 12479, Spartanburg

Teva Investigational Site 12489, Boerne

Teva Investigational Site 12475, Waco

Teva Investigational Site 12491, Burke

Teva Investigational Site 12504, Charlottesville

Teva Investigational Site 12482, Richmond

Teva Investigational Site 12498, Richmond

Teva Investigational Site 12490, Spokane

Teva Investigational Site 12533, Papillion

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02126839 - A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics | Biotech Hunter | Biotech Hunter